TRANSACTIONS Despite being "the new kid on the block", our team has been off to a blazing start across the M&A and Capital Markets landscape FIND OUT MORE David Rosenberg 9/30/25 David Rosenberg 9/30/25 $300,000,000 Notes OfferingCo-Manager Read More David Rosenberg 9/19/25 David Rosenberg 9/19/25 $190,000,000 Preferred Stock OfferingCo-Manager Read More David Rosenberg 9/12/25 David Rosenberg 9/12/25 $17,250,000 Follow-On OfferingSole Book-Runner Read More David Rosenberg 9/8/25 David Rosenberg 9/8/25 $50,000,000 Baby BondLead Book-Runner Read More David Rosenberg 9/4/25 David Rosenberg 9/4/25 $25,000,000 ATM OfferingSole Placement Agent Read More David Rosenberg 8/31/25 David Rosenberg 8/31/25 Acquisition Announced with XOMA Royalty Advisor to Mural Oncology Read More David Rosenberg 8/14/25 David Rosenberg 8/14/25 $58,700,000 Follow-On OfferingSole Book-Runner Read More David Rosenberg 8/7/25 David Rosenberg 8/7/25 $65,000,000 Baby BondLead Book-Runner Read More David Rosenberg 8/6/25 David Rosenberg 8/6/25 $65,000,000 Follow-On OfferingLead Manager Read More David Rosenberg 7/25/25 David Rosenberg 7/25/25 $191,160,000 Follow-On OfferingCo-Manager Read More David Rosenberg 7/25/25 David Rosenberg 7/25/25 $57,000,000 Baby BondLead Book-Runner Read More David Rosenberg 7/18/25 David Rosenberg 7/18/25 $60,000,000 Baby BondLead Book-Runner Read More David Rosenberg 7/17/25 David Rosenberg 7/17/25 $75,000,000 Follow-On OfferingSole Book-Runner Read More David Rosenberg 7/16/25 David Rosenberg 7/16/25 $10,200,000 Follow-On OfferingSole Book-Runner Read More David Rosenberg 7/14/25 David Rosenberg 7/14/25 Merger transaction with HyperLiquid Strategies Fairness Opinion Read More David Rosenberg 7/11/25 David Rosenberg 7/11/25 $5,500,000 Follow-On OfferingSole Book-Runner Read More David Rosenberg 7/11/25 David Rosenberg 7/11/25 $9,200,000 Follow-On OfferingSole Book-Runner Read More David Rosenberg 7/10/25 David Rosenberg 7/10/25 $50,000,000 Series B Term PreferredJoint Book-Runner Read More David Rosenberg 6/30/25 David Rosenberg 6/30/25 Merger transaction with OrthoCellix Fairness Opinion Read More David Rosenberg 6/30/25 David Rosenberg 6/30/25 Merger transaction with Crescent Biopharma Advisor to GlycoMimetics Read More Older Posts
David Rosenberg 9/19/25 David Rosenberg 9/19/25 $190,000,000 Preferred Stock OfferingCo-Manager Read More
David Rosenberg 9/12/25 David Rosenberg 9/12/25 $17,250,000 Follow-On OfferingSole Book-Runner Read More
David Rosenberg 8/31/25 David Rosenberg 8/31/25 Acquisition Announced with XOMA Royalty Advisor to Mural Oncology Read More
David Rosenberg 8/14/25 David Rosenberg 8/14/25 $58,700,000 Follow-On OfferingSole Book-Runner Read More
David Rosenberg 7/17/25 David Rosenberg 7/17/25 $75,000,000 Follow-On OfferingSole Book-Runner Read More
David Rosenberg 7/16/25 David Rosenberg 7/16/25 $10,200,000 Follow-On OfferingSole Book-Runner Read More
David Rosenberg 7/14/25 David Rosenberg 7/14/25 Merger transaction with HyperLiquid Strategies Fairness Opinion Read More
David Rosenberg 7/11/25 David Rosenberg 7/11/25 $5,500,000 Follow-On OfferingSole Book-Runner Read More
David Rosenberg 7/11/25 David Rosenberg 7/11/25 $9,200,000 Follow-On OfferingSole Book-Runner Read More
David Rosenberg 7/10/25 David Rosenberg 7/10/25 $50,000,000 Series B Term PreferredJoint Book-Runner Read More
David Rosenberg 6/30/25 David Rosenberg 6/30/25 Merger transaction with OrthoCellix Fairness Opinion Read More
David Rosenberg 6/30/25 David Rosenberg 6/30/25 Merger transaction with Crescent Biopharma Advisor to GlycoMimetics Read More